# Summary of REMS for FDA-approved CAR T-cell products
| Product                             |CRS grade| Tocilizumab   | Corticosteroids |
| :---                                |:----:|     :----:    |  :----:         |
| Abecma (idecabtagene vicleucel)|Grade 1 (Lee 2014)| If onset 72 hours or more after infusion, treat symptomatically. If onset less than 72 hours after infusion, consider tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg).| Consider dexamethasone 10 mg IV every 24 hours.|
|Abecma (idecabtagene vicleucel)|Grade 2 (Lee 2014)|Administer tocilizumab 8 mg/kg IV over 1 hour (not to exceed 800 mg). Repeat tocilizumab every 8 hours as needed if not responsive to intravenous fluids or increasing supplemental oxygen. Limit to a maximum of 3 doses in a 24-hour period; maximum total of 4 doses.|Consider dexamethasone 10 mg IV every 12 to 24 hours.
